KalVista Pharma Trial of Hereditary Angioedema Treatment Hits Snag

April 21, 2021

The FDA has placed a clinical hold on a KalVista Pharmaceuticals phase 2 trial evaluating its investigational drug, KVD824, for treatment of hereditary angioedema.

The company submitted an Investigational New Drug application earlier this year for the proposed study but the FDA has called for more information on specific preclinical studies, according to the Cambridge, Mass., drugmaker.

“Although we no longer can confirm that the KVD824 phase 2 trial will initiate this quarter, we are working to resolve [the FDA’s] concerns in a timely fashion,” said CEO Andrew Crockett.

View today's stories